Yu MM. Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2? World J Clin Infect Dis 2021; 11(3): 60-62 [DOI: 10.5495/wjcid.v11.i3.60]
Corresponding Author of This Article
Ming-Ming Yu, PhD, Doctor, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266100, Shandong Province, China. mingmingyu@bjmu.edu.cn
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Infect Dis. Nov 5, 2021; 11(3): 60-62 Published online Nov 5, 2021. doi: 10.5495/wjcid.v11.i3.60
Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2?
Ming-Ming Yu
Ming-Ming Yu, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao 266100, Shandong Province, China
Author contributions: Yu MM designed and wrote the letter.
Conflict-of-interest statement: Dr. Yu has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Ming Yu, PhD, Doctor, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266100, Shandong Province, China. mingmingyu@bjmu.edu.cn
Received: June 19, 2021 Peer-review started: June 19, 2021 First decision: July 31, 2021 Revised: August 18, 2021 Accepted: October 20, 2021 Article in press: October 20, 2021 Published online: November 5, 2021 Processing time: 136 Days and 1.6 Hours
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 spread worldwide within only a few months. The screening and timely isolation of infected individuals have been regarded as an effective means of epidemic prevention and control. Therefore, effective screening of infected individuals plays a vital role in epidemic prevention and control. At present, reverse transcription-polymerase chain reaction (RT–PCR) is the main method for the in vitro detection of SARS-CoV-2. However, RT–PCR requires certified laboratories, expensive equipment, and trained technicians. Therefore, it is necessary to develop simpler and more convenient methods. Some studies have shown that the PepKAA peptide has a high affinity for the S protein of SARS-CoV-2. The tyrosine in PepKAA is labeled with 125I and used to design a radioimmunoassay kit for the detection of the S protein of SARS-CoV-2, which is of great significance for the early diagnosis of COVID-19.
Core Tip: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious, and early detection of SARS-CoV-2 is the key factor in preventing another epidemic. Radioimmunoassay (RIA) exhibits high sensitivity and specificity. The detection of the S protein on the surface of SARS-CoV-2 by RIA is expected to be applied for the early diagnosis of coronavirus disease 2019, which may have a considerable impact on the control of the epidemic.
